# M.D. Anderson Cancer Center: Phase 1 study closed enrollment, 119 enrolled (Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma)

**Score:** 40/100

| Field | Value |
|---|---|
| Sponsor | M.D. Anderson Cancer Center |
| Sponsor type | Academic and hospital |
| Study | Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer |
| NCT ID | NCT02600949 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Metastatic Colorectal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7 |
| Intervention types | drug, biological, procedure |
| Target enrollment | 119 |
| Site countries | United States |
| Posted | 2015-11-09 |
| Planned start | 2016-05-11 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-13 |
| Last update posted | 2026-10-13 |

## Why this score
- Enrollment closed: data management, monitoring and closeout ahead.
- 119 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT02600949). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.